hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Launched by INOVIO PHARMACEUTICALS · Nov 8, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed and dated written IRB approved informed consent;
• • 2. Males or females aged ≥18 years;
• * 3. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse post definitive therapy at least 4 and no more than 24 weeks from completion of definitive therapy at the time of signing informed consent as described below for each indication:
• * Breast carcinoma:
• * Lung carcinoma:
• * Pancreatic carcinoma:
• * Head and neck squamous cell carcinoma:
• * Ovarian cancer:
• • Colorectal cancer
• • Gastric and esophageal cancer
• • Hepatocellular carcinoma
• Exclusion Criteria:
• • 1. Previous treatment wth any TERT or IL-12 containing therapy, or any other DNA immunotherapy;
• • 2. Any concurrent condition requiring the continued or anticipated use of systemic steroids (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy (excludes low dose methotrexate). All other systemic corticosteroids must be discontinued at least 4 weeks prior to first Study Treatment;
• • 3. Administration of any vaccine within 4 weeks of the first study treatment